FDA 483 - MFCI (Huanggang) Co., Ltd. - August 14, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspection of MFCI (Huanggang) Co., Ltd. in Huanggang, Hubei, China, revealed significant data integrity issues, including deleted laboratory records and inadequate computer controls. Numerous deficiencies were also found in equipment maintenance, process validation, environmental controls, and quality control procedures for API manufacturing. These observations indicate a systemic lack of adherence to cGMP requirements, posing a risk to product quality and patient safety.
ID · d7ddcda6-a90c-4edd-870b-b2b5047477c8